Pathstone Holdings
BLFS icon

Pathstone Holdings’s BioLife Solutions BLFS Stock Holding History

Pathstone Holdings’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,712
Closed -$403K – 2318
2024
Q1 		$403K Buy
21,712
+360
+2% +$6.29K ﹤0.01% 1789
2023
Q4 		$347K Buy
+21,352
New +$272K ﹤0.01% 1728

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CRM
Cramer Rosenthal McGlynn Stamford, Connecticut $1.36B AUM 31.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pathstone Holdings's BLFS Position: Q2 2024 in Review

Pathstone Holdings sold out of BioLife Solutions (BLFS) in Q2 2024, closing a stake of 21,712 shares — an estimated $403K sold.

Pathstone Holdings first reported a position in BLFS in Q4 2023 and held it in 2 quarters. The position peaked at $403K in Q1 2024. 164 funds tracked by Wall St. Rank hold BLFS as of Q2 2024.

  • Pathstone Holdings reported no remaining BioLife Solutions position as of Q2 2024 after selling out during the quarter.
  • Pathstone Holdings sold 21,712 BioLife Solutions shares in Q2 2024, an estimated $403K.
  • Pathstone Holdings first reported a position in BioLife Solutions in Q4 2023 and held it in 2 quarters.
  • Pathstone Holdings's BioLife Solutions position peaked at $403K in Q1 2024.
  • 164 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2024.

Based on Pathstone Holdings's 13F filing for Q2 2024, filed 14 Aug 2024.